Solace, a digital health platform that connects patients with expert health advocates, announced it has closed a $60 million Series B funding round. Menlo Ventures led this funding round with participation from existing backers Craft Ventures, Inspired Capital, and Torch Capital, and new investor SignalFire.
This funding round reflects the accelerating market conviction that healthcare advocacy is a critical standard of care that drives better outcomes, lowers costs, and enhances patient experiences.
Launched in 2022, Solace was built to fix a broken system and improve health outcomes by prioritizing humans at the center of healthcare. And this funding round validates the founding thesis that personalized healthcare navigation is effective, and essential.
Solace’s EHR and data platform eliminates friction and brings clarity to the modern care journey. And this funding will accelerate development across the patient and advocate experiences while Solace scales its national network of healthcare advocates.
This funding follows a time of rapid growth for Solace, signaling a growing demand for solutions that prioritize people over process in healthcare.
KEY QUOTES:
“The healthcare industry is at a tipping point. Payers increasingly recognize that patient advocacy isn’t a support function. It’s structurally necessary. This investment validates our momentum and the critical role advocacy plays in reshaping the healthcare landscape.”
– Jeremy Gurewitz, CEO and co-founder of Solace
“Solace delivers what legacy systems can’t. Personalized, tech-enabled advocacy that scales. Our platform anticipates needs, guides decisions in real time, and makes advocacy an integral part of every patient’s experience.”
– Sara Sargent, Chief Product Officer and co-founder of Solace
“Our investment in Solace underscores our conviction that healthcare advocacy will quickly become a core component of modern healthcare delivery. Solace’s compelling early data proves not just better patient outcomes, but fundamentally stronger financial and clinical outcomes for payers.”
– JP Sanday, Partner at Menlo Ventures
